Pursuant to a directors resolution passed on Oct. 15, 2024, the company has consolidated its capital on a one-new-for-two-old basis. The name of the company has not been changed.

Effective at the opening on Friday, Oct. 25, 2024, the common shares of Medicus Pharma Ltd. will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a research and development in the physical, engineering and life sciences company.

Postconsolidation

Capitalization:  unlimited shares with no par value, of which 10,846,780 shares are issued and outstanding

Escrow:  923,642 shares subject to escrow

Transfer agent:  Odyssey Trust Company

Trading symbol:  MDCX (unchanged)

Cusip No.:  58471K 20 2 (new)